Vyse S - Search Results

1

De novo mutations implicate novel genes in systemic lupus erythematosus.

Pullabhatla V, Roberts AL, Lewis MJ, Mauro D, Morris DL, Odhams CA, Tombleson P, Liljedahl U, Vyse S, Simpson MA, Sauer S, de Rinaldis E, Syvänen AC, Vyse TJ. Pullabhatla V, et al. Among authors: vyse s. Hum Mol Genet. 2018 Feb 1;27(3):421-429. doi: 10.1093/hmg/ddx407. Hum Mol Genet. 2018. PMID: 29177435 Free PMC article.

2

UBE2L3 polymorphism amplifies NF-κB activation and promotes plasma cell development, linking linear ubiquitination to multiple autoimmune diseases.

Lewis MJ, Vyse S, Shields AM, Boeltz S, Gordon PA, Spector TD, Lehner PJ, Walczak H, Vyse TJ. Lewis MJ, et al. Among authors: vyse s, vyse tj. Am J Hum Genet. 2015 Feb 5;96(2):221-34. doi: 10.1016/j.ajhg.2014.12.024. Epub 2015 Jan 29. Am J Hum Genet. 2015. PMID: 25640675 Free PMC article.

3

Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1.

Lewis MJ, Vyse S, Shields AM, Zou L, Khamashta M, Gordon PA, Pitzalis C, Vyse TJ, D'Cruz DP. Lewis MJ, et al. Among authors: vyse s, vyse tj. Arthritis Res Ther. 2016 Jan 8;18:5. doi: 10.1186/s13075-015-0896-7. Arthritis Res Ther. 2016. PMID: 26746423 Free PMC article.

4

Effect of UBE2L3 genotype on regulation of the linear ubiquitin chain assembly complex in systemic lupus erythematosus.

Lewis M, Vyse S, Shields A, Boeltz S, Gordon P, Spector T, Lehner P, Walczak H, Vyse T. Lewis M, et al. Among authors: vyse s, vyse t. Lancet. 2015 Feb 26;385 Suppl 1:S9. doi: 10.1016/S0140-6736(15)60324-5. Lancet. 2015. PMID: 26312912

5

Next-generation sequencing for the management of sarcomas with no known driver mutations.

Vyse S, Thway K, Huang PH, Jones RL. Vyse S, et al. Curr Opin Oncol. 2021 Jul 1;33(4):315-322. doi: 10.1097/CCO.0000000000000741. Curr Opin Oncol. 2021. PMID: 33927108 Review.

6

Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.

Maguire SL, Peck B, Wai PT, Campbell J, Barker H, Gulati A, Daley F, Vyse S, Huang P, Lord CJ, Farnie G, Brennan K, Natrajan R. Maguire SL, et al. Among authors: vyse s. J Pathol. 2016 Nov;240(3):315-328. doi: 10.1002/path.4778. J Pathol. 2016. PMID: 27512948 Free PMC article.

7

Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer.

Vyse S, Huang PH. Vyse S, et al. Expert Rev Anticancer Ther. 2022 Jan;22(1):3-16. doi: 10.1080/14737140.2022.2016397. Epub 2021 Dec 28. Expert Rev Anticancer Ther. 2022. PMID: 34913823

8

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.

Vyse S, Huang PH. Vyse S, et al. Signal Transduct Target Ther. 2019 Mar 8;4:5. doi: 10.1038/s41392-019-0038-9. eCollection 2019. Signal Transduct Target Ther. 2019. PMID: 30854234 Free PMC article. Review.

9

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.

Harrison PT, Vyse S, Huang PH. Harrison PT, et al. Among authors: vyse s. Semin Cancer Biol. 2020 Apr;61:167-179. doi: 10.1016/j.semcancer.2019.09.015. Epub 2019 Sep 25. Semin Cancer Biol. 2020. PMID: 31562956 Free PMC article. Review.

10

Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors.

Wong JP, Todd JR, Finetti MA, McCarthy F, Broncel M, Vyse S, Luczynski MT, Crosier S, Ryall KA, Holmes K, Payne LS, Daley F, Wai P, Jenks A, Tanos B, Tan AC, Natrajan RC, Williamson D, Huang PH. Wong JP, et al. Among authors: vyse s. Cell Rep. 2016 Oct 25;17(5):1265-1275. doi: 10.1016/j.celrep.2016.10.005. Cell Rep. 2016. PMID: 27783942 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page